NASDAQ$MGNX
MacroGenics Inc · Q1 2020 earnings
Q1 2020 earnings · · Investor relations
Briefing
Reported financial results for the first quarter of 2020 and provided an update on corporate progress.
MacroGenics reported total revenue of $13.7 million for the quarter ended March 31, 2020, compared to $9.7 million for the quarter ended March 31, 2019. Research and development expenses were $48.9 million, and net loss was $44.7 million.
- Observed progress and clinical activity across a broad portfolio of seven antibody-based product candidates.
- Anticipate presenting clinical data from all molecules this year.
- Expect some near-term impact on clinical trial site initiation and patient enrollment due to COVID-19 pandemic.
- Reiterated guidance for the timing of anticipated 2020 clinical data read-outs or regulatory events.
Headline financials
Revenue & EPS history
MacroGenics · Revenue · Quarterly
$13.7M
Revenue by segment
MacroGenics · $13.7M total across 2 segments · Q1 2020
- Collaborative Agreements$13M—94.8%
- Government Agreements$715K—5.2%
Forward guidance
MacroGenics anticipates that its cash, cash equivalents and marketable securities as of March 31, 2020, combined with anticipated and potential collaboration payments, should enable it to fund its operations into 2022, assuming the Company's programs and collaborations advance as currently contemplated.
Historical earnings impact
How earnings announcements have historically affected this stock's price.
Avg. return before/after earnings
Based on 19 quarterly earnings reports · overlaid with Q1 2020
+5.6%
Avg return
Earnings day
+4.0%
Avg return
5 days after
+3.4%
Avg return
30 days after
44%
23 / 52 earnings
Positive
+251.7%
Q1 2020
Best reaction
-77.4%
Q1 2024
Worst reaction
| Quarter | Report date | Reaction (Day 0) | +5 days | +30 days |
|---|---|---|---|---|
| Q1 2026 | -0.9% | +24.0% | +12.9% | |
| Q4 2025 | +45.3% | +27.1% | +45.8% | |
| Q3 2025 | +8.3% | +4.8% | -4.8% | |
| Q1 2025 | +0.0% | +0.0% | -5.1% | |
| Q4 2024 | -4.8% | -25.7% | -40.0% | |
| Q3 2024 | +13.2% | +17.6% | -8.4% | |
| Q2 2024 | -5.6% | -1.7% | -5.6% | |
| Q1 2024 | -77.4% | -69.6% | -69.1% | |
| Q4 2023 | -18.8% | -18.0% | -15.0% | |
| Q3 2023 | +20.0% | +20.5% | +62.7% | |
| Q2 2023 | +26.6% | +13.7% | +4.7% | |
| Q1 2023 | -0.4% | -9.1% | -28.2% | |
| Q4 2022 | +8.4% | +3.7% | +0.6% | |
| Q3 2022 | +22.1% | +30.1% | +42.3% | |
| Q2 2022 | +16.2% | +18.9% | -3.6% | |
| Q1 2022 | -15.2% | -38.2% | -56.5% | |
| Q4 2021 | -3.6% | -8.1% | -12.7% | |
| Q3 2021 | +4.1% | +5.1% | -16.7% | |
| Q2 2021 | -5.5% | -5.7% | -10.3% | |
| Q1 2021 | -8.3% | -9.8% | -8.8% | |
| Q4 2020 | +18.7% | +16.1% | +57.6% | |
| Q3 2020 | +4.9% | +0.9% | +19.9% | |
| Q2 2020 | -1.5% | +3.1% | +5.9% | |
| Q1 2020 | +251.7% | +184.5% | +186.4% | |
| Q4 2019 | +8.5% | -20.8% | -45.5% | |
| Q3 2019 | -0.9% | -6.5% | +13.9% | |
| Q2 2019 | -0.3% | -9.1% | -2.5% | |
| Q1 2019 | +3.4% | +9.7% | +9.4% | |
| Q4 2018 | -2.8% | -5.8% | -19.4% | |
| Q3 2018 | +8.7% | -1.0% | -2.3% | |
| Q2 2018 | +6.3% | +9.5% | +11.1% | |
| Q1 2018 | -9.2% | -7.8% | +2.8% | |
| Q4 2017 | +2.1% | +17.7% | +2.4% | |
| Q3 2017 | -1.6% | -0.3% | +8.9% | |
| Q2 2017 | +6.6% | +8.0% | +17.8% | |
| Q1 2017 | -1.7% | -12.2% | -9.9% | |
| Q4 2016 | -5.1% | -2.7% | -15.8% | |
| Q3 2016 | -16.3% | -6.0% | +10.4% | |
| Q2 2016 | +6.8% | +1.1% | -2.2% | |
| Q1 2016 | -5.8% | — | — | |
| Q4 2015 | +5.1% | — | — | |
| Q3 2015 | -4.4% | — | — | |
| Q2 2015 | -12.1% | — | — | |
| Q1 2015 | +9.5% | — | — | |
| Q4 2014 | -0.2% | — | — | |
| Q3 2014 | +17.5% | — | — | |
| Q2 2014 | -4.8% | — | — | |
| Q2 2013 | -4.8% | — | — | |
| Q1 2014 | -5.0% | — | — | |
| Q1 2013 | -5.0% | — | — | |
| Q4 2013 | -7.6% | — | — | |
| Q3 2013 | +7.3% | — | — | |
| Q4 2012 | — | — | — | |
| Q3 2012 | — | — | — |
Discussion
Share your read of this quarter. Sign-in carries your eToro identity.
Join the conversation
Sign in with eToro to post your read of this quarter and vote on others'.
Sign in with eToro